Menu
Washingtoner
  • Home
  • Artificial Intelligence
  • Health
  • Technology
  • Entertainment
  • Software
  • Business
  • Education
  • Real Estate
Washingtoner

ClearSight Therapeutics Receives U.S. Patent Notice of Allowance
Washingtoner/10337768

Trending...
  • Iglesia.com Positioned in Multimillion-Dollar Domain Market with $10 Million Asking Price
  • New Self-Service Sandbag Station at Tacoma Recovery and Transfer Center
  • The Fifth Annual "Bamboo Lantern Festival" to Illuminate Tokyo Mizumachi and Sumida River Walk®
ClearSight Therapeutics, Inc.
USPTO allows 26 claims for ophthalmic formulations containing quaternary chitosan derivatives, marking a key step toward U.S. patent protection.

DALLAS - Washingtoner -- ClearSight Therapeutics Receives U.S. Patent Notice of Allowance for Ophthalmic Formulation Technology for unmet ocular diseases

Allowance marks an intellectual property milestone for innovative biopolymeric formulations developed for ocular applications


DALLAS, TX — [Release Date] — ClearSight Therapeutics today announced receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 19/380,414, titled "Ophthalmic Solution Containing Quaternary Chitosan Derivatives for Treating Ocular Diseases."

The notice, mailed September 29, 2026, allows 26 claims, including composition and method claims. The allowance represents an important step toward securing U.S. patent protection for ClearSight's ophthalmic formulation technology.

More on Washingtoner
  • A Diwali Celebration with Heritage at South Brunswick Residents & American Properties
  • Law Offices of Larry E. Bray, P.A. Wins Fourth District Appeal Clarifying Limits of Florida's Offer of Judgment Statute
  • Holiday Magic Returns to Downtown Downers Grove November 27-29
  • What If the Greatest Gift This Holiday Season Came in a Dream of Your Loved One in Spirit?
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Minneapolis

"This allowance marks an important milestone for ClearSight and the science behind our ophthalmic formulations," said Patrick Smale, co-founder and CEO of ClearSight Therapeutics. "Building a strong intellectual property foundation supports our mission to develop innovative, accessible eye care solutions. We're encouraged by this progress as we continue advancing our technology."

"The formulation work focused on preserving the efficacy and key properties of quaternary chitosan in an ophthalmic solution," said co-inventor Nuria Jimenez, PhD, and co-founder & co-inventor Suchismita Acharya, PhD. "We're pleased that the examiner recognized the stability and antiviral activity data presented in the application, and we look forward to building on this scientific foundation to develop our eyedrop product to help people and expand our patent portfolio."

In its statement of reasons for allowance, the examiner cited evidence of acceptable formulation stability, preserved antiviral activity, and unexpectedly higher antiviral activity at 8- and 24-hour time points. These findings relate to evidence presented during patent examination and do not establish clinical efficacy or regulatory approval.

More on Washingtoner
  • LGF Lab Gas Flow Launches Fully Automatic Laboratory Gas Changeover Manifold System with Ultra High Purity Gas Regulator Valve
  • Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
  • Inaugural 12 Trees of Christmas gala raises $525,000 for DMG research and family support
  • BitTitan Expands MigrationWiz with SharePoint Sites Migration and Simplified Collaboration Licensing
  • Olympic champion Katie Moon to compete at Pole Vault in Paradise in Key West

About ClearSight Therapeutics

ClearSight Therapeutics is a Dallas/Fort Worth-based company founded in 2023 by eye care industry veterans and partners to develop better solutions for common eye conditions. The company is advancing next-generation over-the-counter ophthalmic products designed to address dryness, irritation, and ocular discomfort. For more information, visit clearsighttx.com.

Media Contact

ClearSight Therapeutics
info@clearsighttx.com
972-983-7761

Contact
ClearSight Therapeutics, Inc.
Patrick Smale
***@clearsighttx.com


Source: ClearSight Therapeutics, Inc.
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • Spokane City Council Passes Chronic Nuisance Properties Ordinance
  • City of Spokane and City Council Announce 2027 Legislative Priorities
  • LCH2 Awarded Additional $1 Million to Advance Lewis County Clean Energy Campus
  • Security Planning Tips For Your Holiday Event From Access Patrol Services
  • Tacoma: Council Member Sandesh Sadalge Focuses Today's District 4 Town Hall on the City's Biennial Budget
  • City of Tacoma Awarded $2.25 Million in Federal Highway Safety Improvement Program Grant Funding for South 21st Street Corridor
  • New Self-Service Sandbag Station at Tacoma Recovery and Transfer Center
  • Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
  • Business News & Info Goes Inside Paragon FX Group's Hunt for Original Film Props
  • Kitchen Table Economics: An Invitation to Think Differently
  • Win a $5,000 VIP Family Experience at the 100th Thanksgiving Day Parade in New York City
  • CB Stuffer Announces Private Sale to Secure Future of Brand Growth
  • The Fifth Annual "Bamboo Lantern Festival" to Illuminate Tokyo Mizumachi and Sumida River Walk®
  • Iglesia.com Positioned in Multimillion-Dollar Domain Market with $10 Million Asking Price
  • Searching for the Next LBE Creator: CalArts Launches First-Ever D.R.E.A.M.S. Pitch Competition
  • TCA VG: 2025 Funding Climbs to $9M across 43 Companies; Cumulative Returns Reach 5.3 MOIC & 22% IRR
  • Spokane: Gesa Pavilion Concert Series Welcomes New Concert Promoter
  • Integris Composites Joins International Sea Power Conference Aboard HMS Prince of Wales
  • Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
  • ViewDNS.info Launches Monitors, Alerting Teams the Moment Something Changes on Their Domains
_catLbl0 _catLbl1

Popular on Washingtoner

  • Pre-Seed VC Martin Tobias Makes Fundraising Tool Available to Every Startup CEO as Investor Match - 324
  • New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX) - 281
  • LocalsVoted Launches: Local Rankings From Phone-Verified Votes, Not Paid Placement - 176
  • Simpalm Staffing Launches Tax Preparer Staffing for U.S. CPA Firms - 145
  • Sycamore Dove Releases "Loving Every Moment" - 121
  • One in three Americans may have lost track of retirement savings from a previous job - 115
  • Datavalet Named One of Quebec's Best Workplaces™ for 2026 - 111
  • Tacoma: OMWBE Active Certification Class on November 16
  • Nextlink Internet Deploys netElastic to Modernize Its Hybrid Broadband Network
  • ThriveStack citedby launches Prompt Research to find the prompts buyers ask in AI search

Similar on Washingtoner

  • Boston Industrial Solutions Introduces the New Volta® M100 Pad Printing Machine
  • What If the Greatest Gift This Holiday Season Came in a Dream of Your Loved One in Spirit?
  • Green Revolution CBD Spotlights Its Water-Soluble Focus Tincture With CBD, CBG and Lion's Mane
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
  • Security Planning Tips For Your Holiday Event From Access Patrol Services
  • Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
  • TCA VG: 2025 Funding Climbs to $9M across 43 Companies; Cumulative Returns Reach 5.3 MOIC & 22% IRR
  • Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
  • Contracting Resources Group Named a 2027 Elev8 GovCon Honoree by OrangeSlices
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute